RANKWEIL, Austria--( BUSINESS WIRE)--Rentschler Fill Solutions GmbH, a CMO and expert for aseptic fill and finish services, today announced a collaboration with Ultragenyx Pharmaceutical, Inc. for the drug product production of the injectable MepseviiTM (vestronidase alfa), a recombinant form of the human enzyme beta-glucuronidase, to treat patients with mucopolysaccharidosis (MPS) VII, a rare genetic disorder.
Rentschler Fill Solutions and Ultragenyx Start Fill & Finish Collaboration for the US Commercial Supply of Drug Product Mepsevii
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться